In This Article:
-
Product Revenue: Increased 97% to $4.7 million for the first six months of fiscal 2025.
-
Product Gross Margin: Increased to 57.9% for the first half of fiscal 2025, more than double from fiscal 2024.
-
License Revenue: $3 million recognized in the first six months of fiscal 2025 from Zimmer distribution agreement.
-
Net Loss: Improved to $0.5 million for the first six months of fiscal 2025, compared to $6.2 million in the same period of fiscal 2024.
-
Operating Expenses: Decreased 4% to $6.7 million for the first six months of fiscal 2025.
-
Cash and Cash Equivalents: $1.3 million as of March 31, 2025.
-
Working Capital: $2 million as of March 31, 2025.
-
No Debt: The company had no debt outstanding as of March 31, 2025.
-
Capital Raise: $8.2 million in net proceeds from an oversubscribed capital raise in April.
-
Fiscal Year 2025 Guidance: Product revenue expected to be $8 million to $10 million, with gross margin between 47% and 51%.
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
NeuroOne Medical Technologies Corp (NASDAQ:NMTC) reported a 97% increase in product revenue to $4.7 million for the first half of fiscal 2025.
-
The company achieved a significant improvement in product gross margins, reaching 57.9%, more than double the margin from the previous year.
-
NeuroOne Medical Technologies Corp (NASDAQ:NMTC) has no debt and anticipates being fully funded through at least fiscal year 2026.
-
The OneRF ablation system has shown clinical success, with the majority of patients treated remaining seizure-free.
-
The company has expanded its strategic partnership with Zimmer Biomet, leveraging their extensive distribution network to drive product adoption.
Negative Points
-
Product revenue in the second quarter of fiscal 2025 remained flat at $1.4 million compared to the same quarter in the previous year.
-
The company experienced a sequential decline in product revenue due to the completion of initial stocking orders to Zimmer Biomet.
-
Operating expenses increased slightly to $3.5 million in the second quarter of fiscal 2025.
-
NeuroOne Medical Technologies Corp (NASDAQ:NMTC) reported a net loss of $2.3 million for the second quarter of fiscal 2025.
-
The company has not yet commercialized its products in international markets, representing an untapped revenue opportunity.
Q & A Highlights
Q: On the guidance, you're talking about $8 million to $10 million, and that's excluding the $3 million from the first quarter, correct? A: Yes, that is correct. That does exclude the licensing fee that we received in the first quarter. - Ron McClurg, CFO